Quantitative Neuromuscular Monitoring Why Are We Still Guessing at Recovery Review Abstract Purpose: This review critically evaluates the scientific rationale, current evidence, professional guideline recommendations, and practical implementation of quantitative neuromuscular monitoring during recovery from neuromuscular blockade, with particular emphasis on patients receiving nondepolarizing neuromuscular blocking
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study
BTK Degraders in CLL/SLL After BTK Inhibitor Failure: A Promising Escape Route Still Under Study Review Abstract Purpose: This review assesses the rationale, emerging clinical evidence, safety considerations, and practical implications of Bruton tyrosine kinase (BTK) degraders in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), particularly after
AI Surgical Coaches: Do They Improve Outcomes, or Just Performance Metrics? What Early Real-World Data Show
AI Surgical Coaches: Do They Improve Outcomes, or Just Performance Metrics? What Early Real-World Data Show Review Abstract Purpose: This review examines the emerging evidence for artificial intelligence-assisted surgical coaching, with particular emphasis on whether these systems improve clinically meaningful outcomes or primarily improve technical-performance and
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians
Can Bispecific Antibodies Move Safely Into the Outpatient Clinic? A Label-Concordant Framework for Clinicians Review Abstract Purpose: This review assesses whether CD3-engaging bispecific antibody therapy can be delivered safely in outpatient oncology settings, with emphasis on cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infection prevention,
From 270 Table Values to a Month-by-Month Pension Valuation Engine
GlobalRPh Retirement Tools From 270 Table Values to a Month-by-Month Pension Valuation Engine How GlobalRPh converted a dense guaranteed-income table into a practical pension calculator, then moved beyond the table to build an advanced 2026 estimator that models timing, mortality, survivor benefits, inflation, and the time value of
Peptide Evidence Without the Hype – New Calculator
GlobalRPh Clinical Technology Peptide Evidence Without the Hype - Peptide Selection Tool Introducing the GlobalRPh Investigational Peptide Evidence and Safety Navigator, a structured evidence mapping program that separates FDA approved peptide medicines from off label research, human investigational programs, preclinical compounds, and products supported primarily by marketing
GlobalRPh Vancomycin Dosing and Bayesian AUC Advanced Calculator
Introducing the GlobalRPh Vancomycin Dosing and Bayesian AUC Calculator Advanced (Beta) Five population models, conventional pharmacokinetics, Bayesian forecasting, and clinician-directed AUC dosing in one platform A formal introduction to the Advanced calculator's conventional AUC workflow, Bayesian mathematics, five population-specific models, model-selection safeguards, and clinician-directed
HIV in the Era of Long-Acting Injectables: Redefining Adherence Without Abandoning Follow-Up
HIV in the Era of Long-Acting Injectables: Redefining Adherence Without Abandoning Follow-Up Reviewed and updated July 29, 2026 Abstract Purpose: This review examines how long-acting injectable antiretroviral therapy and injectable HIV pre-exposure prophylaxis are changing treatment, prevention, and adherence frameworks in HIV care. Methodology: The
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease
Menin Inhibitors in AML: Targeting KMT2A-Rearranged and NPM1-Mutated Disease Review Abstract Purpose Acute myeloid leukemia (AML) is a heterogeneous group of hematologic malignancies defined increasingly by recurrent molecular and cytogenetic abnormalities. KMT2A rearrangements and NPM1 mutations identify biologically distinct leukemias that frequently rely on menin-dependent
Prediabetes in 2026: Evidence Thresholds for Lifestyle Intervention, Metformin, and Anti-Obesity Pharmacotherapy
Prediabetes in 2026: Evidence Thresholds for Lifestyle Intervention, Metformin, and Anti-Obesity Pharmacotherapy Review Abstract Purpose This review examines when lifestyle intervention, metformin, and anti-obesity pharmacotherapy are most appropriate for adults with prediabetes. The objective is to clarify the role of each strategy using current clinical
